CareDx, Inc. - Common Stock (CDNA)

The precision medicine pioneer is helping to improve patient care.

Testing volumes surged 51% as NavDx integration drove revenue and margin gains.

CareDx (NASDAQ:CDNA) reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant business and the addition of Specialty Oncology testing following the July acquisition of Naveris. Revenue for the quarter ended Sept. 30 was $139 million, up 39% from a yea

The diagnostics leader is accelerating the trend toward precision medicine.

CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform. Total revenue rose to $132 million

CareDx, a leader in transplant diagnostics, saw a key insider reduce his direct holdings amid a series of scheduled transactions.

CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

CareDx (CDNA) Q1 2026 Earnings Call Transcript